引入内型概念以应对1型糖尿病疾病异质性挑战
1型糖尿病单一临床表型下存在显著异质性,涉及发病年龄、遗传易感性、进展速度、胰岛素分泌能力及并发症率等。机制和免疫病理研究显示受试者间差异大,阻碍发病机制阐明和临床试验设计。文章提出从表型转向内型(潜在生物学机制)概念,借鉴其他疾病经验 delineate 路线图,以加速精准医学实施并影响转化研究、试验设计和临床管理。
要点
- 1型糖尿病临床异质性显著,单一疾病方法难以维持。
- 内型基于潜在生物学机制,优于基于观察特征的亚型。
- 将内型概念纳入实验室和临床实践可加速精准医学。
核心结论
- 维持1型糖尿病单一疾病方法不可行,需从表型转向内型概念以解析异质性。
- 引入内型概念有望加速精准医学实施并影响转化研究、试验设计和临床管理。
研究设计与样本
- 本文为观点性文章,基于其他疾病经验和迄今收集的数据, delineate 将内型概念纳入实验室和临床实践的路线图。
主要发现
- 1型糖尿病发病年龄覆盖全年龄段,遗传易感性复杂,进展速度和胰岛素分泌能力差异显著。
- 并发症率、血糖控制和治疗干预疗效变异广泛,机制和免疫病理研究显示受试者间斑片状差异。
- 异质性阻碍发病机制解析和疾病修饰剂临床试验的设计、实施与解读。
临床怎么用
- 临床应超越表型分类,依据内型(潜在生物学机制)对1型糖尿病进行分型。
- 将内型概念整合入实验室和临床实践,以推动精准医学和优化临床试验设计。
局限性
- 本文为观点性文章,未提供原始研究数据或系统评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical diagnosis of new-onset type 1 diabetes has, for many years, been considered relatively straightforward. Recently, however, there is increasing awareness that within this single clinical phenotype exists considerable heterogeneity: disease onset spans the complete age range; genetic susceptibility is complex; rates of progression differ markedly, as does insulin secretory capacity; and complication rates, glycemic control, and therapeutic intervention efficacy vary widely. Mechanistic and immunopathological studies typically show considerable patchiness across subjects, undermining conclusions regarding disease pathways. Without better understanding, type 1 diabetes heterogeneity represents a major barrier both to deciphering pathogenesis and to the translational effort of designing, conducting, and interpreting clinical trials of disease-modifying agents. This realization comes during a period of unprecedented change in clinical medicine, with increasing emphasis on greater individualization and precision. For complex disorders such as type 1 diabetes, the option of maintaining the "single disease" approach appears untenable, as does the notion of individualizing each single patient's care, obliging us to conceptualize type 1 diabetes less in terms of phenotypes (observable characteristics) and more in terms of disease endotypes (underlying biological mechanisms). Here, we provide our view on an approach to dissect heterogeneity in type 1 diabetes. Using lessons from other diseases and the data gathered to date, we aim to delineate a roadmap through which the field can incorporate the endotype concept into laboratory and clinical practice. We predict that such an effort will accelerate the implementation of precision medicine and has the potential for impact on our approach to translational research, trial design, and clinical management.
引用
- Battaglia M, Ahmed S, Anderson MS, et al. Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. Diabetes Care. 2019. PMID: 31753960. doi:10.2337/dc19-0880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。